Phase II Trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in Peripheral T-cell non-Hodgkin Lymphoma (SWOG S0350)

BACKGROUND: Peripheral T-cell lymphomas (PTCLs) have an inferior progression-free (PFS) and overall survival (OS) compared to aggressive B-NHL. Since PTCLs over-express MDR-1/P-gp, we devised PEGS with agents which are not substrates of the efflux pump. Gemcitabine was included due to excellent sing...

Full description

Saved in:
Bibliographic Details
Main Authors: Mahadevan, D., Unger, J. M., Spier, C.M., Persky, D.O., Young, F., LeBlanc, M., Fisher, R.I., Miller, T.P.
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3485430/
https://ncbi.nlm.nih.gov/pubmed/22833464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.27733
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items